Previously, we demonstrated that STAT6 decoy ODN was able to inhibit TNF-a or IL-6 release from murine mast cells stimulated with IgE receptor engagement. 7 In addition, STAT6 decoy ODN was able to inhibit P-selectin expression on human dermal microvascular endothelial cells (HDMEC) induced by substance P and ⁄or IL-4 stimulation. 9 Human dermal fibroblasts and epidermal keratinocytes can produce eosinophil chemoattractants, such as eotaxin and eotaxin-3, when stimulated with IL-4. 10 Thus, STAT6 decoy ODN possibly attenuated the skin inflammation of AD by the inhibition of IL-4 ⁄IL-13-mediated signals, leading to the decreased production of pro-inflammatory cytokines and eosinophil chemoattractants, as well as to diminished expression of cell adhesion molecules.Although this was an investigator-initiated, open-label pilot study, the findings presented in this study revealed the reliable therapeutic efficacy of topical STAT6 decoy ODN on the skin inflammation of patients with AD.

No abstract

No abstract

No abstract

No abstract